Systemic Therapy for Ovarian Cancer, Current Treatment, Recent Advances, and Unmet Needs

  • Susana BanerjeeEmail author
  • Michael A. Bookman
  • Martin Gore


Ovarian cancer is the second most common gynaecological malignancy and the leading cause of death from gynaecological cancer. Most women present with advanced disease with little prospect of cure. The optimal management of epithelial ovarian cancer involves a multidisciplinary approach incorporating surgical staging, cytoreduction, and platinum-based chemotherapy in appropriate patients. There has been little overall change in the incidence and mortality rates from ovarian cancer over the past three decades, but improvements in survival times and quality of life have occurred as a result of key advances in both surgical and chemotherapeutic strategies. In this introductory chapter, we summarise the existing treatments for epithelial ovarian cancer, introduce recent advances, and highlight unmet needs in the treatment of epithelial ovarian cancer.


Ovarian cancer Treatment 


  1. Aebi S, Castiglione M (2009). Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):21–23.PubMedCrossRefGoogle Scholar
  2. Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, et al. (1996). Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–55.CrossRefGoogle Scholar
  3. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43.PubMedCrossRefGoogle Scholar
  4. Ashworth A (2008). A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785–90.CrossRefGoogle Scholar
  5. Audeh MW, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Carmichael J, Tutt A (2009). Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 27(Suppl; abstr 5500).Google Scholar
  6. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, et al. (2008). Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26:3709–14.CrossRefGoogle Scholar
  7. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, et al. (2000). BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60:5329–33.Google Scholar
  8. Banerjee S, Gore M (2009). The future of targeted therapies in ovarian cancer. Oncologist 14:706–16.CrossRefGoogle Scholar
  9. Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, et al. (2006). Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 102:432–39.CrossRefGoogle Scholar
  10. Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J Jr, et al. (2004). Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22:3507–16.CrossRefGoogle Scholar
  11. Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF (2009). Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 27:418–25.Google Scholar
  12. Blackledge G, Lawton F, Redman C, Kelly K (1989). Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59:650–53.CrossRefGoogle Scholar
  13. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. (2008). Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626–32.CrossRefGoogle Scholar
  14. Bookman MA (2005). Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. Int J Gynecol Cancer 15(Suppl 1):12–17.PubMedCrossRefGoogle Scholar
  15. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. (2009). Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419–25.CrossRefGoogle Scholar
  16. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR (2003). Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21:283–90.CrossRefGoogle Scholar
  17. Bookman MA, McMeekin DS, Fracasso PM (2006). Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol 103:473–78.CrossRefGoogle Scholar
  18. Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, Smyth JF (2002). CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 8(7):2233–2239.Google Scholar
  19. Bristow RE, Chi DS (2006). Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103:1070–76.Google Scholar
  20. Buda A, Floriani I, Rossi R, Colombo N, Torri V, Conte PF, et al. (2004). Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian collaborative study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) Group and I.O.R. (Istituto Oncologico Romagnolo) Group. Br J Cancer 90:2112–17.Google Scholar
  21. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI (2007). Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:5165–71.Google Scholar
  22. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. (2007). Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180–86.Google Scholar
  23. Cantu MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, et al. (2002). Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20:1232–37.CrossRefGoogle Scholar
  24. Chan J, Tain C, Fleming G, Monk B, Herzog T, Kapp D, et al. (2010). The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early stage high risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group Study. Gynecol Oncol Mar;116(3):301–6.PubMedCrossRefGoogle Scholar
  25. Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, et al. (2008). Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group Study. Cancer 112:2202–10.CrossRefGoogle Scholar
  26. Chura JC, Van Iseghem K, Downs LS Jr, Carson LF, Judson PL (2007). Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 107:326–30.CrossRefGoogle Scholar
  27. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, et al. (2007). AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6:2209–19.CrossRefGoogle Scholar
  28. Del Campo JM, Roszak A, Bidzinski M, Ciuleanu TE, Hogberg T, Wojtukiewicz MZ, et al. (2009). Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol Nov;20(11):1764–802.Google Scholar
  29. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W et al. (2003). A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320–1329.PubMedGoogle Scholar
  30. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, et al. (2005). 2004 consensus statements on the management of ovarian cancer: final document of the 3rd international Gynecologic Cancer Intergroup ovarian cancer consensus conference (GCIG OCCC 2004). Ann Oncol 16(Suppl 8):viii7–viii12.PubMedCrossRefGoogle Scholar
  31. du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, et al. (2006). Addition of epirubicin as a third drug to carboplatin–paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized Gynecologic Cancer Intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. J Clin Oncol 24:1127–35.CrossRefGoogle Scholar
  32. Dumontet C, Jordan MA, Lee FF (2009). Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 8:17–25.PubMedCrossRefGoogle Scholar
  33. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–21.CrossRefGoogle Scholar
  34. Fennelly D, Aghajanian C, Shapiro F, O’Flaherty C, McKenzie M, O’Connor C, et al. (1997). Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15:187–92.Google Scholar
  35. Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, et al. (2008). Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26:890–96.CrossRefGoogle Scholar
  36. Fojo T, Bates S (2003). Strategies for reversing drug resistance. Oncogene 22:7512–23.CrossRefGoogle Scholar
  37. Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman JS (2003). Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a Gynecologic Group Study. J Clin Oncol 21:2856–59.CrossRefGoogle Scholar
  38. Galmarini CM, Mackey JR, Dumontet C (2001). Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15:875–90.CrossRefGoogle Scholar
  39. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. (2008). Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26:76–82.PubMedCrossRefGoogle Scholar
  40. Glasspool RM, Gore M, Rustin G, et al. (2009). Randomized phase II study of decitabine in combination with carboplatin compared with carboplatin alone in patients with recurrent advanced ovarian cancer. Clin Oncol 27(15s, (Suppl; abstr 5562)).Google Scholar
  41. Glinsky GV (2008). “Stemness” genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol 26:2846–53.CrossRefGoogle Scholar
  42. Gonzalez-Martin AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A, et al. (2005). Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol 16:749–55.CrossRefGoogle Scholar
  43. Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Irwin DH, et al. (2005). Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 15:785–92.CrossRefGoogle Scholar
  44. Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, et al. (2006). Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24:4324–32.CrossRefGoogle Scholar
  45. Gordon AN, Tonda M, Sun S, Rackoff W (2004). Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95:1–8.PubMedCrossRefGoogle Scholar
  46. Gore ME, Atkinson RJ, Thomas H, Cure H, Rischin D, Beale P, et al. (2002b). A phase II trial of ZD0473 in platinum-pretreated ovarian cancer. Eur J Cancer 38:2416–20.CrossRefGoogle Scholar
  47. Gore ME, Fryatt I, Wiltshaw E, Dawson T (1990). Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207–11.CrossRefGoogle Scholar
  48. Gore M, Oza A, Rustin G, Malfetano J, Calvert H, Clarke-Pearson D, et al. (2002a). A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 38:57–63.PubMedCrossRefGoogle Scholar
  49. Gore M, ten Bokkel Huinink W, Carmichael J, Gordon A, Davidson N, Coleman R, et al. (2001). Clinical evidence for topotecan–paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 19:1893–900.Google Scholar
  50. Gossage L, Madhusudan S (2007). Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 33:565–77.CrossRefGoogle Scholar
  51. Group ICON (2002). Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360:505–15.CrossRefGoogle Scholar
  52. Guminski AD, Harnett PR, deFazio A (2001). Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line – a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemother Pharmacol 48:229–34.CrossRefGoogle Scholar
  53. Han ES, Monk BJ (2007). What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 105:3–6.PubMedCrossRefGoogle Scholar
  54. Harter P, Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. (2006). Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13:1702–10.CrossRefGoogle Scholar
  55. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. (2006). Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S161–S92.Google Scholar
  56. Holzer AK, Howell SB (2006). The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 66:10944–52.CrossRefGoogle Scholar
  57. Hoskins PJ, Vergote I, Stuart G, et al. (2008). Phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (EOC) (OV.16). A Gynecologic Cancer Intergroup Study of the NCIC CTG, EORTC GCG, and GEICO. J Clin Oncol 26, Abstract LBA5505.Google Scholar
  58. Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, et al. (2007). Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 105:211–17.CrossRefGoogle Scholar
  59. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009). Cancer statistics. CA Cancer J Clin 59:225–49.CrossRefGoogle Scholar
  60. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, et al. (2009). Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet Oct 17;374(9698):1331–8.Google Scholar
  61. Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, et al. (2007). A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 97:1618–24.CrossRefGoogle Scholar
  62. Kristensen GB, Vergote I, Stuart G, Del Campo JM, Kaern J, Lopez AB, et al. (2003). First-line treatment of ovarian cancer FIGO stages IIb–IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer 13(Suppl 2):172–77.CrossRefGoogle Scholar
  63. Kumar L, Hariprasas R, Kumar S (2007). Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery versus upfront surgery followed by chemotherapy (CT) in advanced epithelial ovarian carcinoma (EOC): A prospective randomized study – Interim results. J Clin Oncol 25, abstr 5531.Google Scholar
  64. Larue L, Bellacosa A (2005). Epithelial–mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 24:7443–54.CrossRefGoogle Scholar
  65. Ledermann JA, Rustin GJ, Hackshaw A, Kaye SB, Jayson G, Gabra H, James LE, Bell S, Temple G (2009). A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). J Clin Oncol 27, suppl; abstr 5501.Google Scholar
  66. Lhomme C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, et al. (2008). Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 26:2674–82.CrossRefGoogle Scholar
  67. Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, Waggoner S (2006). Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group Study. Gynecol Oncol 101:436–40.CrossRefGoogle Scholar
  68. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. (2001). Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001–7.Google Scholar
  69. Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, et al. (2009). Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 114:195–98.Google Scholar
  70. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, et al. (2003). Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460–65.Google Scholar
  71. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. (1991). Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389–93.Google Scholar
  72. Matei D, Sill MW, DeGeest K, Bristow RE (2008). Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. J Clin Oncol 26, May 20 suppl; abstr 5537.Google Scholar
  73. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, et al. (2009). Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27:5601–6.CrossRefGoogle Scholar
  74. McGonigle KF, Muntz HG, Vuky JL, et al. (2008). Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer (OC). J Clin Oncol 26, 305s (abstract 5551).Google Scholar
  75. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6.PubMedCrossRefGoogle Scholar
  76. Micha JP, Goldstein BH, Rettenmaier MA, Genesen M, Graham C, Bader K, et al. (2007). A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 17:771–76.CrossRefGoogle Scholar
  77. Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, et al. (2009). Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the Gynecologic Oncology Group. J Clin Oncol 27:2686–91.CrossRefGoogle Scholar
  78. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (2006). Cellular pharmacology of gemcitabine. Ann Oncol 17(Suppl 5):v7–v12.PubMedCrossRefGoogle Scholar
  79. Mizuno M, Kikkawa F, Shibata K, Kajiyama H, Ino K, Kawai M, et al. (2006). Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol 94:138–43.CrossRefGoogle Scholar
  80. Monk J, Herzog T, Kaye S, Krasner C, Vermorken J, Muggia F, et al. (2008). A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC). ESMO 33rd Congress: abstr LBA4.Google Scholar
  81. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. (2000). Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 18:106–15.Google Scholar
  82. Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, et al. (2008). Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 110:49–55.PubMedCrossRefGoogle Scholar
  83. Omura GA, Brady MF, Look KY, Averette HE, Delmore JE, Long HJ, et al. (2003). Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: An intergroup study. J Clin Oncol 21:2843–48.Google Scholar
  84. Ovarian Cancer (2009). NCCN Clinical Practice Guidelines in Oncology V.2.2009.Google Scholar
  85. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003). Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194–3200.PubMedCrossRefGoogle Scholar
  86. Papadimitriou CA, Markaki S, Siapkaras J, Vlachos G, Efstathiou E, Grimani I, Hamilos G, Zorzou M, Dimopoulos MA (2004). Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 66(2):112–117.CrossRefGoogle Scholar
  87. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin 55:74–108.PubMedCrossRefGoogle Scholar
  88. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. (2003). Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099–106.Google Scholar
  89. Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, et al. (2009). Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: Final results of the After-6 Protocol 1. J Clin Oncol 27:4642–48.CrossRefGoogle Scholar
  90. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, et al. (2006). Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699–707.CrossRefGoogle Scholar
  91. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. (2000a). Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 92:699–708.PubMedCrossRefGoogle Scholar
  92. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–72.CrossRefGoogle Scholar
  93. Posadas EM, Liel MS, Kwitkowski V, Minasian L, Godwin AK, Hussain MM, Espina V, Wood BJ, Steinberg SM, Kohn EC (2007). A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 109(7):1323–1330.PubMedCrossRefGoogle Scholar
  94. Piccart MJ, Green JA, Lacave AJ, Reed N, Vergote I, Benedetti-Panici P, Bonetti A, Kristeller-Tome V, Fernandez CM, Curran D et al. (2000b). Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 18(6):1193–1202.PubMedGoogle Scholar
  95. Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, Shih Ie M (2005). Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 65:1994–2000.PubMedCrossRefGoogle Scholar
  96. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, et al. (2008). Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8:17.PubMedCrossRefGoogle Scholar
  97. Pujade-Lauraine E, Mahner S, Kaern J, Gebski V, Heywood M, Vasey P, et al. (2009). A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J Clin Oncol 27, abstr LBA5509.Google Scholar
  98. Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, et al. (2003). A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 88:130–35.CrossRefGoogle Scholar
  99. Rose PG, Blessing JA, Mayer AR, Homesley HD (1998). Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 16:405–10.Google Scholar
  100. Rose P, Edwards R, Finkler N, Seiden M, Duska L, Krasner C, et al. (2007). Phase 3 study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC). J Clin Oncol 25, abstr LBA5529.Google Scholar
  101. Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe B, Puistola U, et al. (2002). Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 41:418–24.CrossRefGoogle Scholar
  102. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE (1996). Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 7:361–64.Google Scholar
  103. Rustin GJ, van der Burg ME, collaborators oboMaE (2009). A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol, 18s: abstr 1.Google Scholar
  104. Scarfone G, Scambia G, Raspagliesi F, et al. (2006). A multicenter, randomized, phase III study comparing paclitaxel/carboplatin (PC) versus topotecan/paclitaxel/carboplatin (TPC) in patients with stage III (residual tumor > 1 cm after primary surgery) and IV ovarian cancer (OC). J Clin Oncol 24, (Suppl 18S):Abstract 5003.Google Scholar
  105. Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, et al. (2005). Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 11:5539–48.CrossRefGoogle Scholar
  106. Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, et al. (2005). Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 23:1867–74.CrossRefGoogle Scholar
  107. Sharom FJ (2008). ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 9:105–27.CrossRefGoogle Scholar
  108. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, et al. (2005). Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29:218–24.Google Scholar
  109. Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams AR, et al. (2007). Antiestrogen therapy is active in selected ovarian cancer cases: The use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 13:3617–22.CrossRefGoogle Scholar
  110. Swart A (2007). Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1). J Clin Oncol 25, abstr 5509.Google Scholar
  111. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, et al. (2006). Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 103:11154–59.CrossRefGoogle Scholar
  112. ten Bokkel Huinink W, Lane SR, Ross GA (2004). Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 15:100–3.CrossRefGoogle Scholar
  113. Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ, et al. (2009). Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 27:1426–31.CrossRefGoogle Scholar
  114. Tew WPCN, Ray-Coquard I, et al. (2007). VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study. J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I 25(18S (June 20 Supplement): 5508).Google Scholar
  115. Thigpen J (2009). Ovarian Cancer: Recent Developments in the Standard of Care and Emerging Options. Clinical Care Options/Oncology.Google Scholar
  116. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ (1994). Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group Study. J Clin Oncol 12:1748–53.Google Scholar
  117. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. (2008). Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14:5198–208.CrossRefGoogle Scholar
  118. Trimble EL, Davis J, Disaia P, Fujiwara K, Gaffney D, Kristensen G, et al. (2007). Clinical trials in gynecological cancer. Int J Gynecol Cancer 17:547–56.CrossRefGoogle Scholar
  119. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S et al. (2003). International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95(2):105–112.PubMedCrossRefGoogle Scholar
  120. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. (1995). The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European organization for research and treatment of cancer. N Engl J Med 332:629–34.Google Scholar
  121. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, et al. (2004). Phase III randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682–91.Google Scholar
  122. Vergote I, Calvert H, Kania M, Kaiser C, Zimmermann AH, Sehouli J (2009a). A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer 45:1415–23.Google Scholar
  123. Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, et al. (2001). Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357:176–82.CrossRefGoogle Scholar
  124. Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, et al. (2009b). Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 45:2324–32.Google Scholar
  125. Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, et al. (2000). Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst 92:1534–5.CrossRefGoogle Scholar
  126. Vergote I, Trope C, Amant F, Kristensen G, Sardi J, Ehlen T, et al. (2008). EORTC–GCG/NCIC–CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIc–IV ovarian, fallopian tube and peritoneal cancer (ovca). 12th Biennial Mtg Intl Gynecol Cancer Soc. abstract 1767.Google Scholar
  127. Wagner U, du Bois A, Pfisterer J, Huober J, Loibl S, Luck HJ, et al. (2007). Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum–taxane based therapy – A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol 105:132–37.CrossRefGoogle Scholar
  128. Welch S, Hirte H, Elit L, et al. (2007). CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib – A trial of the PMH Phase II Consortium. J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I 25(18S (June 20 Supplement): 551).Google Scholar
  129. Williams CJ (2001). Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev 2010, Mar 17;3:CD001034.Google Scholar
  130. Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. (2007). Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:3621–27.CrossRefGoogle Scholar
  131. Winter-Roach BA, Kitchener HC, Dickinson HO (2009). Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev 2009, Jul 8;(3):CD004706.Google Scholar
  132. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, et al. (2005). Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11:6422–30.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Susana Banerjee
    • 1
    Email author
  • Michael A. Bookman
    • 2
  • Martin Gore
    • 3
  1. 1.Medical OncologyThe Royal Marsden HospitalLondonUK
  2. 2.Hematology–OncologyArizona Cancer CenterTucsonUSA
  3. 3.The Royal Marsden NHS Foundation Trust and The Institute of Cancer ResearchLondonUK

Personalised recommendations